Langerhans cells in human chronic gingivitis and phenytoin-induced gingival hyperplasia.
Langerhans cell numbers in oral epithelium increase as dental plaque accumulates. The anti-convulsant drug phenytoin predisposes to gingival hyperplasia in certain patients who take this medication for epilepsy and who also have poor oral hygiene. In this study 7 patients with phenytoin-induced gingival hyperplasia were compared with 5 subjects with chronic marginal gingivitis. On initial examination and on completion of the hygiene phase of periodontal therapy (a period ranging from 3.0 to 4.25 months), clinical indices of plaque and gingivitis were recorded and biopsies were taken from the lower anterior labial gingiva. Frozen sections were stained by an immunoperoxidase technique using the monoclonal antibody OKT6, and the number of Langerhans cells in a defined cross-sectional area was counted. In phenytoin-induced gingival hyperplasia there was a marked increase in Langerhans cells (13.8 +/- 0.45) when compared with chronic gingivitis (7.7 +/- 0.31; p less than 0.05). Both groups showed marked reductions in their plaque and gingival indices and numbers of Langerhans cells once treatment had been completed. However, levels of Langerhans cells in the drug-induced hyperplasia remained significantly higher (3.5 +/- 0.26) than in chronic gingivitis (1.5 +/- 0.22; p less than 0.05).
Kinane
D F
DF
Department of Oral Medicine and Pathology, Glasgow Dental Hospital and School, Scotland.
Drummond
J R
JR
Chisholm
D M
DM
D000328:Adult; D002452:Cell Count; D002908:Chronic Disease; D003773:Dental Plaque / Q000473:pathology; D005885:Gingival Hyperplasia / Q000139:chemically induced / Q000473:pathology*; D005891:Gingivitis / Q000473:pathology*; D006801:Humans; D007801:Langerhans Cells / Q000473:pathology*; D010672:Phenytoin / Q000009:adverse effects
D010672:Phenytoin